Bicycle Therapeutics plc (50BA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bicycle Therapeutics plc (50BA) has a cash flow conversion efficiency ratio of -0.097x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-49.61 Million ≈ $-57.99 Million USD) by net assets (€510.25 Million ≈ $596.54 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Bicycle Therapeutics plc market capitalisation for the company's overall valuation and market capitalisation.
Bicycle Therapeutics plc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Bicycle Therapeutics plc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Bicycle Therapeutics plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bicycle Therapeutics plc ranked by their cash flow conversion efficiency. See 50BA debt coverage from operations to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kao Hsiung Chang Iron & Steel Corp
TW:2008
|
-0.001x |
|
Vidhi Specialty Food Ingredients Limited
NSE:VIDHIING
|
0.137x |
|
EPACK Durable Limited
NSE:EPACK
|
-0.218x |
|
Stack Capital Group Inc
TO:STCK
|
-0.009x |
|
HIL Limited
NSE:HIL
|
0.049x |
|
Taisol Electronics Co Ltd
TW:3338
|
0.002x |
|
Compugen
TA:CGEN
|
0.049x |
|
Allpark Empreendimentos Participações e Serviços S.A
SA:ALPK3
|
1.176x |
Annual Cash Flow Conversion Efficiency for Bicycle Therapeutics plc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Bicycle Therapeutics plc from 2018 to 2025. View Bicycle Therapeutics plc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €609.98 Million ≈ $713.13 Million |
€-249.68 Million ≈ $-291.90 Million |
-0.409x | -97.07% |
| 2024-12-31 | €793.06 Million ≈ $927.17 Million |
€-164.72 Million ≈ $-192.58 Million |
-0.208x | -76.51% |
| 2023-12-31 | €370.93 Million ≈ $433.66 Million |
€-43.65 Million ≈ $-51.03 Million |
-0.118x | +63.00% |
| 2022-12-31 | €270.78 Million ≈ $316.57 Million |
€-86.11 Million ≈ $-100.67 Million |
-0.318x | -644.30% |
| 2021-12-31 | €346.25 Million ≈ $404.81 Million |
€-14.79 Million ≈ $-17.30 Million |
-0.043x | +77.07% |
| 2020-12-31 | €95.46 Million ≈ $111.60 Million |
€-17.79 Million ≈ $-20.80 Million |
-0.186x | +39.30% |
| 2019-12-31 | €93.20 Million ≈ $108.96 Million |
€-28.61 Million ≈ $-33.45 Million |
-0.307x | -182.21% |
| 2018-12-31 | €-69.83 Million ≈ $-81.63 Million |
€-26.08 Million ≈ $-30.49 Million |
0.373x | -- |
About Bicycle Therapeutics plc
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide … Read more